While clear therapeutic activity of STING agonists has been shown in preclinical tumor models, early-phase clinical trials with these agents in cancer patients, either as monotherapy or in combination with immune checkpoint inhibitors, have so far shown lack of efficacy26–28. This evidence concerns the gene STING1 and neoplasm.